drugset / Trial / NCT05194007

Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease

NCT05194007 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a pilot, prospective, double-blinded, two-arm, randomized controlled trial of the efficacy of Frondanol in comparison to placebo in decreasing bowel inflammation in patients with a clinical diagnosis of inflammatory bowel disease who are in remission and on standard of care treatment.

Timeline

Start
2022-02-19
Primary completion
2024-11-19
Completion
2024-11-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Frondanol Unknown 1000 mg Oral